Expression of the mutant MEF2BD38V allele was induced in germinal centre- derived B cells by crossing with C<U+03B3>1-Cre mice.
| Inventor | Institute |
|---|---|
| Riccardo Dalla-Favera | The Trustees of Columbia University in the City of New York |
| SKU: | 154096 |
|---|---|
| Product description: | Diffuse large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) are the two most common forms of mature B cell lymphoid neoplams, accounting for over 50% of all diagnoses. Mutant MEF2B (MEF2BD83V) is the most common lymphoma associated oncogene. MEF2BD83V expression in mice leads to GC enlargement and lymphoma development, a phenotype that becomes fully penetrant in combination with BCL2 de-regulation, an event associated with human MEF2B mutations. Expression of the mutant MEF2BD38V allele was induced in germinal centre- derived B cells by crossing with C1-Cre mice. |
| Alternate name: | Myocyte Enhancer Factor 2B, Serum Response Factor-Like Protein 2, RSRFR2, XMEF2 |
| Conditional description: | Conditional Knockin mice that express mutant MEF2BD38V upon recombination by Cre-recombinase |
| Genetic background: | The conditional Mef2bstopD83V allele was generated by introducing a single nucleotide change by site directed mutagenesis leading to the D83V amino-acid change in exon 3. The neomycin-resistance marker followed by a triple-polyA, flanked by two loxP sites was introduced upstream the exon 3 carrying the D83V mutation. Correctly targeted mouse ES cells were injected into blastocysts derived from C57BL/6 mice to generate chimeras. |
| Production details: | The conditional Mef2bstopD83V allele was generated by introducing a single nucleotide change by site directed mutagenesis leading to the D83V amino-acid change in exon 3. The neomycin-resistance marker followed by a triple-polyA, flanked by two loxP sites was introduced upstream the exon 3 carrying the D83V mutation. Correctly targeted mouse ES cells were injected into blastocysts derived from C57BL/6 mice to generate chimeras. |
| Cat. #: | 154096 |
|---|---|
| Research Fields: | Cancer; Immunology |
| Target: | MEF2B |
| Disease: | B-Cell Lymphoma |
| Model: | Knock-In |
| Zygosity: | Homozygous |
| Strain: | C57BL/6 |
| Shipping conditions: | Embryo/Spermatoza- Dry Ice |
|---|
| References: |
Brescia et al. 2018. Cancer Cell. 34(3):453-465.e9. PMID: 30205047. MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.